Asset and Brand planning – what do we do differently when the future has shifted?
With much talk of a changed pharma and biotech market landscape, we ask Jon Bircher, Chief Commercial Officer of Cello Health, and Carl...
Contributors
-
Account Manager -
-
Associate Consultant -
President, USA -
Vice President, Business Development -
Senior Consultant -
-
Publications Executive -
Project Director -
-
Strategic Communications Director -
Associate Consultant -
-
Executive Chairman -
Consultant -
-
Senior Consultant -
Consultant -
Senior Consultant -
SVP -
Master Practitioner: Patient Insights -
Publications Assistant -
EVP, Oncology Practice Head -
-
Chief Commercial Officer -
US CEO -
-
Senior Consultant -
Associate Editorial Director
-
Sr. Research Analyst -
Associate Consultant -
Principal -
Research Executive -
Account Director -
Consultant -
-
Head of MedErgy (CH-MedErgy) -
-
Managing Consultant -
Marketing and Communications Manager -
Project Manager -
Project Manager -
Managing Consultant -
Project Director -
Executive Vice President, Strategic Collaborations -
Associate Consultant -
Associate Consultant
Cello Health Archive
- June 2020 (1)
- May 2020 (1)
- April 2020 (2)
- March 2020 (6)
- February 2020 (19)
- January 2020 (4)
- December 2019 (3)
- November 2019 (4)
- October 2019 (1)
- September 2019 (2)
- August 2019 (4)
- July 2019 (4)
- June 2019 (4)
- May 2019 (12)
- April 2019 (11)
- March 2019 (5)
- February 2019 (12)
- January 2019 (1)
- October 2018 (2)
- August 2018 (5)
- July 2018 (7)
- June 2018 (5)
- May 2018 (5)
- April 2018 (6)
- March 2018 (9)
- February 2018 (11)
- January 2018 (4)
- December 2017 (8)
- November 2017 (21)
- October 2017 (35)
- September 2017 (18)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- May 2017 (2)
- April 2017 (2)
- March 2017 (1)
- February 2017 (2)
- January 2017 (1)
- December 2016 (1)
- October 2016 (1)
When the Wheels fall off the Brand Planning Cycle
COVID-19 is disrupting working life as we all know it. In the context of the annual brand planning cycle, we caught up with Jane Ayton...
“Plans Are Worthless, But Planning Is Everything” - Biotech leaders discuss key challenges in self-commercialization for late-stage assets
In early February, Cello Health Consulting’s Carl Engleman moderated a panel discussion with senior biotech leaders at the LSX World...
Rare Diseases, cell therapies and the value conundrum - food for thought
Considerations around ‘value’ assessment for gene and cell therapies in rare diseases was a theme addressed by several speakers, to close...
Kite (a Gilead company) release unpublished data demonstrating the key determinants influencing durable responses in large B cell lymphoma patients treated with YESCARTA CAR-T therapy
Dr. Adrian Bot (VP of Translational Medicine – Kite, a Gilead Company) provides an update on the factors determining durable responses...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net